EW on XNYS, Health Care, Edwards Lifesciences Corp, job postings
Measures activity, not value. Not investment advice.
Net income fell 25% over 12 months while quarterly revenue rose 10% to $1.7B.
GoodShares up 15% in one month and 21% over the past year
BadApplications to hire foreign specialists fell 35%, to 41 from 63
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
expected around 9 Feb 2027 (an estimate: a year ago it reported on 10 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.7B, net income $307.5M.
31 Dec 2021RevenueNet incometallest bar $3.1B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$1.7B
$307.5M
30 Jun 2026
$1.7B
$241.9M
31 Mar 2026
$1.6B
$380.7M
31 Dec 2025
–
$91.2M
30 Sep 2025
$1.6B
$291.1M
30 Jun 2025
$1.5B
$333.2M
31 Mar 2025
$1.4B
$358.0M
31 Dec 2024
$1.4B
$385.6M
30 Sep 2024
$1.4B
$3.1B
30 Jun 2024
$1.4B
$366.3M
31 Mar 2024
$1.6B
$351.9M
31 Dec 2023
$1.3B
$369.9M
30 Sep 2023
$1.5B
$384.9M
30 Jun 2023
$1.5B
$307.1M
31 Mar 2023
$1.5B
$340.5M
31 Dec 2022
$1.3B
$398.4M
30 Sep 2022
$1.3B
$343.5M
30 Jun 2022
$1.4B
$406.4M
31 Mar 2022
$1.3B
$373.6M
31 Dec 2021
$1.3B
$335.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$6.7B
$5.9B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+13%
+8.1%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$1.0B
$1.4B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$1.77
$2.32
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
78.0%
78.2%
61.3%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
21.6%
24.2%
5.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
15.3%
23.2%
-2.7%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
9.7%
-20.0%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$1.4B
$804.2M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$4.6B
$3.8B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$598.8M
$598.2M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$4.0B (net cash)
-$3.2B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.06
0.22
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$18.89
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
57.3
27.5
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
8.8
2.6
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
8.2
3.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
5.4
3.4
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$10.9M
bought $0, sold $10.9M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+1.9%
1,332 13F filers vs 1,307
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
88%
506.9M shares held by 13F filers (30 Sep 2026) of 575.0M outstanding (31 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
1.6%
9.4M shares sold short (30 Oct 2026) of 575.0M outstanding (31 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.8
9.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+0.5%
9.3M shares sold short in the report before, 9.4M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
45%
45% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
362
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
-35%
41 vs 63 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+10%
$1.7B vs $1.6B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+11%
$63.6M vs $57.5M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$28.8M
the 12 months before: $28.1M
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$1.3M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
25
25 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.0×
25 articles in the last 7 days; its usual week has 5.
Price $101.85 on 20 Nov 2026, +21% over 12 months (12-month range $75.87 to $107.15)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $34.1M in the last 12 months (the 12 months before: -$13.6M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 41 published in the last 12 months, -35% on the 12 months before.Revenue per quarter. Revenue $1.7B in the latest quarter, +10% on a year earlier.Capital spending per quarter. Capital spending $63.6M in the latest quarter, +11% on a year earlier.Institutional holders (13F filers). 1,332 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.Federal obligations. Federal obligations: $29.6M published in the last 12 months, +8.6% on the 12 months before.Lobbying spend. Lobbying spend: $1.3M published in the last 12 months, -8.0% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $1.3B, +12% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $1.3B, +10% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $1.4B, -0.2% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $1.3B, +0.7% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $1.3B, +1.4% on a year earlier; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $1.5B, +8.8% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $1.5B, +11% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $1.5B, +12% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $1.3B, -6.1% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2024: $1.6B, +9.5% on a year earlier; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $1.4B, -9.4% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $1.4B, -8.5% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $1.4B, +9.4% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $1.4B, -12% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.5B, +11% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $1.6B, +15% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $1.6B, +17% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $1.7B, +14% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $1.7B, +10% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $89.8M, -21% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $72.7M, -31% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $43.1M, -38% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $59.9M, -1.3% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $68.9M, -23% on a year earlier; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $61.5M, -15% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $47.9M, +11% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $55.3M, -7.7% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $88.3M, +28% on a year earlier; public on 13 Feb 2024
Quarter ended 31 Mar 2024: $65.3M, +6.2% on a year earlier; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $85.4M, +78% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $51.9M, -6.1% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $49.8M, -44% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $56.0M, -14% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $49.3M, -42% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $57.5M, +11% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $97.4M, +96% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $64.9M, +16% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $66.9M, +36% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $63.6M, +11% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 1,169; public on 14 Feb 2022
31 Mar 2022 report: 1,215; public on 16 May 2022
30 Jun 2022 report: 1,189; public on 15 Aug 2022
30 Sep 2022 report: 1,138; public on 14 Nov 2022
31 Dec 2022 report: 1,108; public on 14 Feb 2023
31 Mar 2023 report: 1,155; public on 15 May 2023
30 Jun 2023 report: 1,171; public on 14 Aug 2023
30 Sep 2023 report: 1,116; public on 14 Nov 2023
31 Dec 2023 report: 1,143; public on 14 Feb 2024
31 Mar 2024 report: 1,205; public on 15 May 2024
30 Jun 2024 report: 1,225; public on 14 Aug 2024
30 Sep 2024 report: 1,124; public on 14 Nov 2024
31 Dec 2024 report: 1,164; public on 14 Feb 2025
31 Mar 2025 report: 1,144; public on 15 May 2025
30 Jun 2025 report: 1,195; public on 14 Aug 2025
30 Sep 2025 report: 1,188; public on 14 Nov 2025
31 Dec 2025 report: 1,276; public on 17 Feb 2026
31 Mar 2026 report: 1,258; public on 15 May 2026
30 Jun 2026 report: 1,307; public on 14 Aug 2026
30 Sep 2026 report: 1,332; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $254K published
Month from 1 Dec 2021: $1.4M published
Month from 1 Jan 2022: $1.3M published
Month from 1 Feb 2022: $1.5M published
Month from 1 Mar 2022: $1.9M published
Month from 1 Apr 2022: $1.8M published
Month from 1 May 2022: $2.5M published
Month from 1 Jun 2022: $1.1M published
Month from 1 Jul 2022: $1.4M published
Month from 1 Aug 2022: $1.9M published
Month from 1 Sep 2022: $2.1M published
Month from 1 Oct 2022: $2.1M published
Month from 1 Nov 2022: $1.8M published
Month from 1 Dec 2022: $1.8M published
Month from 1 Jan 2023: $1.7M published
Month from 1 Feb 2023: $1.7M published
Month from 1 Mar 2023: $1.5M published
Month from 1 Apr 2023: $1.5M published
Month from 1 May 2023: $2.2M published
Month from 1 Jun 2023: $1.1M published
Month from 1 Jul 2023: $1.9M published
Month from 1 Aug 2023: $2.4M published
Month from 1 Sep 2023: $2.2M published
Month from 1 Oct 2023: $3.2M published
Month from 1 Nov 2023: $1.8M published
Month from 1 Dec 2023: $2.2M published
Month from 1 Jan 2024: $1.7M published
Month from 1 Feb 2024: $3.1M published
Month from 1 Mar 2024: $2.5M published
Month from 1 Apr 2024: $1.8M published
Month from 1 May 2024: $2.1M published
Month from 1 Jun 2024: $2.4M published
Month from 1 Jul 2024: $2.9M published
Month from 1 Aug 2024: $2.5M published
Month from 1 Sep 2024: $2.4M published
Month from 1 Oct 2024: $2.6M published
Month from 1 Nov 2024: $1.9M published
Month from 1 Dec 2024: $2.3M published
Month from 1 Jan 2025: $1.8M published
Month from 1 Feb 2025: $1.7M published
Month from 1 Mar 2025: $2.5M published
Month from 1 Apr 2025: $1.8M published
Month from 1 May 2025: $2.7M published
Month from 1 Jun 2025: $2.3M published
Month from 1 Jul 2025: $3.5M published
Month from 1 Aug 2025: $2.3M published
Month from 1 Sep 2025: $2.2M published
Month from 1 Oct 2025: $2.0M published
Month from 1 Nov 2025: $2.2M published
Month from 1 Dec 2025: $3.0M published
Month from 1 Jan 2026: $1.5M published
Month from 1 Feb 2026: $2.0M published
Month from 1 Mar 2026: $2.0M published
Month from 1 Apr 2026: $3.3M published
Month from 1 May 2026: $2.7M published
Month from 1 Jun 2026: $3.0M published
Month from 1 Jul 2026: $2.3M published
Month from 1 Aug 2026: $2.2M published
Month from 1 Sep 2026: $3.4M published
Month from 1 Oct 2026: $2.3M published
Month from 1 Nov 2026: $1.8M published
Lobbying spend
Quarter from 1 Jan 2022: $340K published
Quarter from 1 Apr 2022: $260K published
Quarter from 1 Jul 2022: $330K published
Quarter from 1 Oct 2022: $310K published
Quarter from 1 Jan 2023: $350K published
Quarter from 1 Apr 2023: $430K published
Quarter from 1 Jul 2023: $370K published
Quarter from 1 Oct 2023: $330K published
Quarter from 1 Jan 2024: $380K published
Quarter from 1 Apr 2024: $430K published
Quarter from 1 Jul 2024: $380K published
Quarter from 1 Oct 2024: $350K published
Quarter from 1 Jan 2025: $390K published
Quarter from 1 Apr 2025: $350K published
Quarter from 1 Jul 2025: $360K published
Quarter from 1 Oct 2025: $280K published
Quarter from 1 Jan 2026: $350K published
Quarter from 1 Apr 2026: $340K published
Quarter from 1 Jul 2026: $280K published
Quarter from 1 Oct 2026: $300K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $1.7B (30 Sep 2026), 1.2× its normal quarter; higher than 99% of its own history.
In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.
Filed
What happened
Source
19 Nov 2026
Entered Amended and Restated Five Year Credit Agreement with Bank of America, N.A. as Administrative Agent, amending and restating the Jul 15, 2022 credit agreementSame filing: took on new debt
362 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 9%, Software engineering 9%, Manufacturing & production 7%, Test, quality & reliability 6%.
Reported lobbying spend: $300K in Q3 2026, $280K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
13 Nov 2026
New
Marshall & Popp, LLCfor Edwards Lifesciences, LLC
Issues related to medical device manufacturing, federal health program reimbursement, trade and tariffs.Health issues, Medicare/Medicaid, Taxation, Budget, Trade
Alpine Group Partners, LLC.for Edwards Lifesciences
Issues related to medical device tax repeal; Issues related to diagnosis and treatment of structural heart disease; Issues related to coverage of medical devices Breakthrough technology designation associated with medicare reimbursementTaxation, Health issues, Medicare/Medicaid
BGR Government Affairsfor Edwards Lifesciences LLC
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issuesHealth issues
Two or more unrelated kinds of records unusual within 30 days
17 Mar 2026confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Edwards Lifesciences(EW): spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year, while it had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year. Two unrelated kinds of activity within 19 days.
Financials: Quarterly capital spending jump, became public on 26 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Mar 2026
The quarter ended 31 Dec 2025 against the 8 quarters before it.
this quarterearliernormal: $56.8MSee the evidence (2 changes)
Financials: Quarterly capital spending jump became public on 26 Feb 2026
Edwards Lifesciences spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.
This period
$97.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$56.8M
Typical spread (median absolute deviation)
$7.2M
How far from its usual level
+3.8
Same quarter last year
$49.8M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $56.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 11 Mar 2026
Edwards Lifesciences had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.
This period
12.4M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
7.9M
Typical spread (median absolute deviation)
675K
How far from its usual level
+4.5
Same report last year
8.5M
History used
2,982 days
the 27 Feb 2026 report24 earlier reportsnormal: 7.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year, while it had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year. Two unrelated kinds of activity within 19 days.
See the evidence (2 changes)
Financials: Quarterly capital spending jump became public on 26 Feb 2026
Edwards Lifesciences spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.
This period
$97.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$56.8M
Typical spread (median absolute deviation)
$7.2M
How far from its usual level
+3.8
Same quarter last year
$49.8M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $56.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 11 Mar 2026
Edwards Lifesciences had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.
This period
12.4M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
7.9M
Typical spread (median absolute deviation)
675K
How far from its usual level
+4.5
Same report last year
8.5M
History used
2,982 days
the 27 Feb 2026 report24 earlier reportsnormal: 7.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
11 Mar 2026Short interest and volume change
had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.
Same report last year: 8.5M; its normal report is 7.9M.
See the evidence
This period
12.4M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
7.9M
Typical spread (median absolute deviation)
675K
How far from its usual level
+4.5
Same report last year
8.5M
History used
2,982 days
the 27 Feb 2026 report24 earlier reportsnormal: 7.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.
Same quarter last year: $49.8M; its normal quarter is $56.8M.
See the evidence
This period
$97.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$56.8M
Typical spread (median absolute deviation)
$7.2M
How far from its usual level
+3.8
Same quarter last year
$49.8M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $56.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 16.9M shares sold short in the 15 Mar 2023 report, 3.8× the same report last year.
Same report last year: 4.5M; its normal report is 6.6M.
See the evidence
This period
16.9M (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
6.6M
Typical spread (median absolute deviation)
1.7M
How far from its usual level
+4.2
Same report last year
4.5M
History used
1,902 days
the 15 Mar 2023 report24 earlier reportsnormal: 6.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 13.7M shares sold short in the 31 Jan 2023 report, 2.4× the same report last year.
Same report last year: 5.8M; its normal report is 6.3M.
See the evidence
This period
13.7M (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
6.3M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.1
Same report last year
5.8M
History used
1,859 days
the 31 Jan 2023 report24 earlier reportsnormal: 6.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 13.9M shares sold short in the 13 Jan 2023 report, 2.6× the same report last year.
Same report last year: 5.4M; its normal report is 6.0M.
See the evidence
This period
13.9M (the 13 Jan 2023 report)
Normal report (median of 24 earlier)
6.0M
Typical spread (median absolute deviation)
948K
How far from its usual level
+5.6
Same report last year
5.4M
History used
1,841 days
the 13 Jan 2023 report24 earlier reportsnormal: 6.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 15.3M shares sold short in the 30 Dec 2022 report, 2.8× the same report last year.
Same report last year: 5.5M; its normal report is 5.8M.
See the evidence
This period
15.3M (the 30 Dec 2022 report)
Normal report (median of 24 earlier)
5.8M
Typical spread (median absolute deviation)
758K
How far from its usual level
+8.5
Same report last year
5.5M
History used
1,827 days
the 30 Dec 2022 report24 earlier reportsnormal: 5.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 14.0M shares sold short in the 15 Dec 2022 report, 2.5× the same report last year.
Same report last year: 5.5M; its normal report is 5.8M.
See the evidence
This period
14.0M (the 15 Dec 2022 report)
Normal report (median of 24 earlier)
5.8M
Typical spread (median absolute deviation)
751K
How far from its usual level
+7.4
Same report last year
5.5M
History used
1,812 days
the 15 Dec 2022 report24 earlier reportsnormal: 5.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.0M shares sold short in the 30 Nov 2022 report, 1.9× the same report last year.
Same report last year: 5.7M; its normal report is 5.7M.
See the evidence
This period
11.0M (the 30 Nov 2022 report)
Normal report (median of 24 earlier)
5.7M
Typical spread (median absolute deviation)
643K
How far from its usual level
+5.5
Same report last year
5.7M
History used
1,797 days
the 30 Nov 2022 report24 earlier reportsnormal: 5.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.6M shares sold short in the 15 Nov 2022 report, 1.9× the same report last year.
Same report last year: 5.5M; its normal report is 5.7M.
See the evidence
This period
10.6M (the 15 Nov 2022 report)
Normal report (median of 24 earlier)
5.7M
Typical spread (median absolute deviation)
643K
How far from its usual level
+5.1
Same report last year
5.5M
History used
1,782 days
the 15 Nov 2022 report24 earlier reportsnormal: 5.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 86 entries; narrow the window or the kind of data to see older ones.
Not listed: 724 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it